Dry Eye Treatment Insurance Denied? How to Appeal

Dry eye disease (DED) ranges from mildly irritating to genuinely debilitating. For patients with moderate to severe chronic dry eye — classified under ICD-10 H04.12 (dry eye syndrome) — the condition impairs vision, interferes with daily activities, and requires active medical management far beyond what lubricating drops from a drugstore shelf can provide. Yet prescription dry eye treatments like Restasis (cyclosporine ophthalmic emulsion 0.05%), Xiidra (lifitegrast 5% ophthalmic solution), Cequa (cyclosporine 0.09%), and in-office procedures like LipiFlow thermal pulsation are routinely denied by insurers who try to categorize these treatments as unnecessary or cosmetic. Here is how to build the case that your dry eye treatment is medically necessary.

Why Dry Eye Treatment Gets Denied

Dry eye denials follow predictable patterns that, once identified, are directly addressable with the right documentation:

• "Not medically necessary" for prescription anti-inflammatory drops: Restasis and Xiidra are FDA-approved prescription medications for chronic dry eye disease — not over-the-counter artificial tears. Despite this, insurers routinely deny them by arguing that clinical documentation does not clearly establish a diagnosis of chronic inflammatory dry eye as opposed to occasional dryness or transient discomfort. Without explicit TFOS DEWS II grading of severity and documented Schirmer test results or corneal staining scores, claims are vulnerable to this denial.
• Step therapy requirements: Many plans require documented failure of over-the-counter artificial tears (used for a defined period, often 90 days or more) before approving Restasis or Xiidra. If your physician prescribed the medication without a documented OTC trial, the insurer will often deny on step therapy grounds.
• Cosmetic treatment classification: LipiFlow and similar thermal pulsation procedures that treat meibomian gland dysfunction (MGD) — a leading cause of evaporative dry eye — are sometimes denied as cosmetic or experimental. This classification contradicts the TFOS DEWS II report, which establishes MGD treatment as a therapeutic intervention for a recognized ocular disease.
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained: In-office dry eye procedures frequently require prior authorization that was not requested before the visit. Even if the procedure is clinically appropriate, the claim may be denied on procedural grounds.
• Vision vs. medical benefit confusion: Dry eye treatment falls under the medical benefit, not the vision benefit. Claims submitted under the wrong benefit category are denied automatically, even if coverage would otherwise apply.

How to Appeal a Dry Eye Treatment Denial

Step 1: Identify Whether the Denial Is Clinical or Administrative

Before building your clinical argument, confirm whether the denial was for a clinical reason (not medically necessary, experimental) or an administrative reason (prior authorization missing, wrong benefit category, step therapy not met). Administrative denials are often the easiest to reverse — a corrected submission or prior authorization request may resolve the issue immediately.

Step 2: Obtain the Insurer's Specific Coverage Policy

Request the insurer's written clinical coverage criteria for the specific treatment denied. Cigna, Aetna, UHC, and most major carriers publish clinical policy bulletins — these bulletins set out exactly what documentation the insurer requires to approve Restasis, Xiidra, or in-office procedures. Matching your documentation to these criteria directly is more effective than a general appeal.

Step 3: Gather Objective Diagnostic Evidence

Your ophthalmologist or optometrist should document the severity of your dry eye disease using objective clinical measures: Schirmer I test results (measuring tear production), corneal and conjunctival staining scores (Oxford scale or van Bijsterveld scale), tear break-up time (TBUT), and meibography results if MGD is the underlying cause. The TFOS DEWS II diagnostic criteria provide the internationally recognized framework; your appeal should demonstrate that your condition meets the threshold for moderate to severe DED requiring prescription intervention.

Step 4: Address the Step Therapy Requirement Directly

If the denial cited failure to attempt OTC treatment first, have your physician write a Letter of Medical Necessity documenting why OTC artificial tears are clinically inadequate for your specific condition. For inflammatory dry eye disease, artificial tears do not address the underlying immune-mediated inflammation — Restasis and Xiidra target the T-cell mediated inflammatory cycle. The physician letter should explicitly state this distinction and explain why anti-inflammatory therapy is the appropriate first-line treatment for this patient's presentation.

Step 5: Submit the Internal Appeal With Peer-Reviewed Literature

Include references to the TFOS DEWS II report (Ocular Surface, 2017), FDA prescribing information for the denied medication, and peer-reviewed studies supporting the efficacy of the specific treatment in patients with comparable presentations. For LipiFlow, cite published randomized controlled trials demonstrating its superiority over conventional warm compresses for MGD-related evaporative dry eye.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review if Internal Appeal Fails

If the insurer upholds the denial internally, request an independent external review. External reviewers apply broadly recognized medical standards — including those established by the American Academy of Ophthalmology (AAO) preferred practice patterns — rather than the insurer's proprietary criteria. For denials where objective diagnostic evidence clearly supports a prescription treatment, external reviews frequently result in reversal.

What to Include in Your Dry Eye Appeal

• Physician Letter of Medical Necessity citing ICD-10 H04.12, TFOS DEWS II severity grading, and clinical rationale for prescription treatment over OTC alternatives
• Objective diagnostic test results: Schirmer test, TBUT, corneal staining scores, and meibography if applicable
• Documentation of OTC treatments attempted (product, duration, outcome) or clinical explanation for why OTC alternatives are insufficient
• FDA prescribing information for Restasis or Xiidra confirming these are prescription drugs for chronic dry eye disease, not cosmetic products
• Peer-reviewed literature from the American Academy of Ophthalmology or TFOS DEWS II supporting the clinical appropriateness of the requested treatment

Fight Back With ClaimBack

Dry eye treatment denials often rest on the insurer's claim that your condition is insufficiently severe or that conservative care has not been tried — arguments that crumble when objective diagnostic documentation is properly assembled. ClaimBack generates a professional appeal citing your specific diagnostic results, AAO guidelines, and your insurer's own coverage criteria in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal